Evaluation of Pharmacokinetics, Safety, and Efficacy of Risankizumab in Pediatric Patients Aged 6 to <18 Years with Moderate to Severe Plaque Psoriasis
- Trial ID
- 2023-504156-10-00
- Protocol
- M19-977
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to evaluate the **pharmacokinetics**, safety, and efficacy of **risankizumab** in pediatric patients aged 6 to less than 18 years with moderate to severe **plaque psoriasis**. The clinical relevance of this objective lies in determining whether the safety and efficacy profile of risankizumab in this younger population is comparable to that observed in adults, thereby potentially expanding treatment options for pediatric patients with this condition.
Participants
The clinical trial involves a total of **71 participants** diagnosed with **plaque psoriasis**. The study population consists of both male and female subjects aged between 6 to less than 18 years, indicating a focus on the pediatric demographic. Participants were selected based on their diagnosis of chronic plaque psoriasis for at least six months prior to the baseline visit, with stable moderate to severe disease as defined by specific body surface area involvement and scoring criteria. The trial includes individuals who are candidates for systemic therapy, as assessed by the investigator. The study does not specify any particular lifestyle considerations such as diet or physical activity. The trial population includes a vulnerable group, given the pediatric nature of the participants. The selection criteria ensure that the participants meet the disease activity requirements at both the screening and baseline visits.
Plans and Procedures
The clinical trial is designed to evaluate the pharmacokinetics, safety, and efficacy of **risankizumab** in pediatric patients aged 6 to less than 18 years with moderate to severe **plaque psoriasis**. This is a randomized, active-controlled, efficacy assessor-blinded study. The trial is structured to compare the effects of risankizumab with a comparator, **ustekinumab**, both administered as a **solution for injection** via the subcutaneous route. The study is expected to conclude by August 2025, with recruitment having commenced in October 2021.
Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as a diagnosis of chronic plaque psoriasis for at least six months and being a candidate for systemic therapy. Following the screening, participants will enter the baseline phase, where initial assessments will be conducted. The primary endpoints include achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) and a static Physician's Global Assessment (sPGA) score of clear or almost clear at Week 16. Secondary endpoints will assess further improvements in PASI scores and quality of life indices.
The trial will involve multiple follow-up visits to monitor the participants' response to treatment and any adverse effects. The end-of-study visit will conclude the trial for each participant, assessing the long-term outcomes of the treatment. The expected duration of participant involvement is up to 40 weeks, depending on the treatment arm and response. Conditions that may lead to early termination from the study include significant adverse reactions or failure to adhere to the study protocol.
Treatment
The clinical trial involves the administration of **Stelara (Ustekinumab)**, a solution for injection, as an experimental medication. This pharmaceutical product is provided in two forms: a 45 mg solution for injection in a vial and a pre-filled syringe (PFS). The active substance, **ustekinumab**, is a protein of non-specific origin. The medication is administered subcutaneously with a maximum daily dose of 90 mg and a total dose of 180 mg over a treatment period of up to 40 weeks. The administration schedule and participant compliance are monitored to ensure adherence to the dosing regimen.
Another experimental medication used in the trial is **Risankizumab**, also provided as a solution for injection in a pre-filled syringe. The active substance, **risankizumab**, is similarly a protein of non-specific origin. This medication is administered subcutaneously with a maximum total dose of 275 mg over a treatment period of up to 40 weeks. The dosing schedule is designed to optimize therapeutic outcomes while monitoring participant compliance throughout the study.
The trial also includes the use of **ABBV-066**, which is another formulation of **Risankizumab**. This solution for injection in a pre-filled syringe is administered subcutaneously with a maximum daily dose of 150 mg and a total dose of 750 mg over a treatment period of up to 40 weeks. The administration of this medication is carefully monitored to ensure participant adherence to the prescribed dosing schedule.
No non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatments, are specified in the trial data provided. The focus remains on evaluating the pharmacokinetics, safety, and efficacy of the experimental medications in the pediatric population with moderate to severe plaque psoriasis.
Efficacy
Efficacy in this clinical trial will be assessed using several primary and secondary endpoints. The co-primary endpoints include the achievement of PASI 75, defined as at least 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI), and the achievement of a static Physician's Global Assessment (sPGA) score of clear or almost clear (0 or 1) at Week 16 of the initial treatment phase. Secondary endpoints will further evaluate efficacy through the achievement of PASI 90 and PASI 100, representing 90% and 100% improvement from baseline in PASI, respectively, at Week 16 of the initial treatment. Additional secondary endpoints include the assessment of PASI 50, PASI 75, PASI 90, and PASI 100 at Week 0 and Week 16 of the retreatment phase in Part 2, as well as changes in the Children's Dermatology Life Quality Index (CDLQI), Family Dermatology Life Quality Index (FDLQI), and Itch Numerical Rating Scale (Itch NRS) from Week 0 to Week 16 of both the initial and retreatment phases.
The efficacy parameters will be measured at specified timepoints, including Week 0, Week 16 of the initial treatment, and Week 16 of the retreatment phase. The PASI and sPGA scores will be utilized as validated scales to quantify the severity and extent of **plaque psoriasis**. Patient-reported outcomes such as CDLQI, FDLQI, and Itch NRS will be collected to assess the impact of the disease and treatment on quality of life and symptom severity. These assessments will be conducted in a manner that ensures the reliability and validity of the data collected, contributing to a comprehensive evaluation of the treatment's efficacy in the pediatric population with moderate to severe plaque psoriasis.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Diagnosis of chronic plaque psoriasis for at least 6 months before the Baseline Visit.
- Stable severe or moderate to severe plaque psoriasis as defined in each study part by body surface area (BSA) psoriasis involvement and scores on the PASI and sPGA.
- Candidate for systemic therapy as assessed by the investigator and meet the disease activity criteria at both the Screening and Baseline Visits per the protocol.
Exclusion Criteria
- Concurrent clinically significant medical conditions other than the indication being studied or any other reason that the investigator determines would interfere with the participant's participation in this study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk by participating in the study.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Germany | Not Recruiting | 01 Oct 2021 | 29 |
Poland | Not Recruiting | 01 Oct 2021 | 28 |
Spain | Not Recruiting | 01 Oct 2021 | 15 |
Sites & Investigators
Research sites
Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
StelaraUstekinumab | Comparator | SOLUTION FOR INJECTION | SUBCUTANEOUS | 90 | 40 | PRD10369914 |
StelaraUstekinumab | Comparator | SOLUTION FOR INJECTION | SUBCUTANEOUS | 90 | 4 | PRD10370091 |
Risankizumab | Test | SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE | SUBCUTANEOUS | 00 | 40 | PRD9422583 |
ABBV-066 | Test | SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE | SUBCUTANEOUS | 150 | 40 | PRD10369455 |



